Login to Your Account



In The Clinic NEWS
TAIPEI, Taiwan – Medigen Biotechnology Corp. said following a meeting Sunday with an independent committee to discuss results midway through the multinational phase III trial for PI-88, the company's adjuvant treatment of hepatocellular carcinoma after surgical resection, preliminary results showed no improvement of survival rates over placebo.
U.S. FILING BY END OF YEAR
With partner Sanofi SA, Regeneron Pharmaceuticals Inc. opened investors' eyes wider by making public the positive outcomes of nine phase III trials with alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in hypocholesterolemia.
Shares of Targacept Inc. (NASDAQ:TRGT) fell to a 52-week low of $2.76 Tuesday after the company disclosed late Monday that it was sacking lead compound TC-5214 in the treatment of overactive bladder (OAB) after top-line phase IIb findings failed to show statistical significance in improving urinary incontinence.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: